Sign in
CompletedNo phase

Effectiveness and Safety of Partition Multi-point Defocused Myopia Management Spectacle Lens in Myopia Control

Key facts

Who runs it
Zhongshan Ophthalmic Center, Sun Yat-sen University
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
194 people enrolled
Started
20 Mar 2023
Ended
27 May 2025
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Partition defocus myopia management spectacle lens
  • Spectacle lenses with aspherical lenslets
Record updated
12 March 2026

Who can take part

Age
8 years to 13 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 14 criteriaShow less

Who can take part

  • Aged 8 to 13 years
  • Under the condition of bilateral cycloplegic autorefraction, the spherical refractive error of -0.75 to -4.75 D in each eye and astigmatism of not more than 1.50 D and anisometropia of not more than 1.00 D
  • Best-corrected visual acuity of equal or better than 0.00 LogMAR (>= 1.0 as Snellen)
  • The intraocular pressure of 10 to 21mmHg
  • Volunteer to participate in this clinical trial with signature of the informed consent form

Who cannot take part

  • Participation of the drug clinical trial within three month and the device clinical trial within one month
  • Participation of any myopia control clinical research trial within three months, and currently using rigid contact lenses (including nursing products), multifocal contact lenses, progressive multifocal lenses and other specially designed myopia control lenses, atropine drugs, etc
  • History of eye injury or intraocular surgery
  • Ocular disease, such as uveitis and other inflammatory diseases, glaucoma, cataract, fundus diseases, eye tumors, dominant strabismus, and any eye diseases that affect visual function
  • Systemic diseases causing low immunity (such as diabetes, Down's syndrome, rheumatoid arthritis, psychotic patients or other diseases that researchers think are not suitable for wearing glasses)
  • Clinically abnormal slit-lamp findings
  • Abnormal fundus examination
  • Only one eye meets the inclusion criteria
  • Unable to have regular follow-up

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Myopia is considered to be the most common type of refractive error, and the incidence of myopia has shown a trend of low age. Recent studies found that the new aspheric microlens spectacle lens can more effectively control the progress of diopter than the single-vision spectcale lens. A new technology of equivalent defocusing around the lens called the partition multi-point defocus optical technology is adopted in this study.

The 2 groups in the trial

  • Intervention groupTreatment being tested

    The participants wear the partition defocus myopia management spectacle lens.

    Treatment: Partition defocus myopia management spectacle lens

  • Control groupExisting treatment, for comparison

    spectacle lenses with aspherical lenslets

    Treatment: Spectacle lenses with aspherical lenslets

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Effectiveness and Safety of Partition Multi-point Defocused Myopia Management Spectacle Lens in Myopia Control Compared With Spectacle Lenses With Aspherical Lenslets: a Randomised Non-inferiority Trial
Record updated
12 March 2026